Speciality Medicines Ltd IPO
Pharmaceuticals
Price Band
₹117 – ₹124
Lot Size
1000
Minimum Bid Quantity
2000
Minimum Investment
₹248000
Issue Size
₹29.14Cr
Opens
2026-03-20
Closes
2026-03-24
Listing
30-03-2026
Subscription Status
Qualified Institutional Buyers
96.24 x
Non-Institutional Investor
1.75 x
Retail Individual Investor
0.78 x
Total
2.14 x
IPO Details
Issue Type
FP
Face Value
₹10
Tick Size
1
ISIN
INE0R0M01014
Pre-Apply Available
No
Daily Bidding Time
10:00:00 - 17:00:00
About the Company
Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceutical products used in the treatment of complex and chronic medical conditions. These products are primarily used in therapeutic areas such as oncology, immunology, neurology, and rare diseases. The company offers a portfolio of speciality medicines available in multiple dosage forms, including tablets, capsules, syrups, injections, infusions, inhalers, creams, gels, ointments, eye drops, nasal sprays, oral solutions, and suspensions. Its operations follow two integrated models: contract manufacturing of approved finished formulations through third-party manufacturers in India for international distribution and marketing and distribution of speciality pharmaceutical products sourced from manufacturers. Under the distribution model, the company handles procurement, warehousing, and wholesale supply of medicines to healthcare providers and retailers. As of March 31, 2025, the company’s portfolio included more than 900 products, and its distribution network covered more than 20 states in India and over 35 countries globally.
Pros
- • Speciality Medicines Limited has a diversified presence across both domestic and international markets. The company operates in more than 35 countries, including markets in Asia, Europe, Africa, and the Middle East. This geographic spread allows the company to generate revenue from multiple regions rather than relying solely on the Indian market.
- • The company claims to maintain a diversified product portfolio within the pharmaceutical sector. As of March 31, 2025, its portfolio included more than 900 pharmaceutical products across several therapeutic categories such as chronic diseases, vaccines, critical care, and anti-infectives. These products are available in multiple dosage forms, including tablets, capsules, liquids, injectables, ointments, creams, and sachets.
- • The company operates through two integrated business models within the pharmaceutical supply chain. These include contract manufacturing of finished formulations through third-party manufacturers in India for international markets and the marketing and distribution of speciality pharmaceutical products sourced from other manufacturers. This structure allows the company to participate in both manufacturing coordination and distribution activities.
Cons
- • One of the company’s promoters and directors is involved in an ongoing criminal proceeding related to allegations under the IPC, the Drugs and Cosmetics Act, and the Essential Commodities Act. The case relates to allegations of price manipulation and black marketing of pharmaceutical products and is currently pending before the Gujarat High Court after interim relief was granted. Any adverse decision in this case could lead to penalties, reputational damage, and operational disruptions for the company.
- • The company depends heavily on a limited number of customers for a significant portion of its revenue. The top five customers contributed Rs 35.52 crore (60.95%), Rs 11.86 crore (43.09%), and Rs 13.54 crore (58.42%) to revenue from operations in FY25, FY24, and FY23, respectively, while the top 10 customers contributed Rs 43.64 crore (74.90%), Rs 16.89 crore (61.36%), and Rs 16.42 crore (70.86%) during the same period. Any failure to retain these key customers or a decline in business from them can adversely affect the company’s revenue and financial performance.
- • The company relies on a limited number of suppliers for its pharmaceutical products. The largest supplier accounted for purchases of Rs 12.15 crore (23.58%) in FY25, Rs 4.97 crore (22.95%) in FY24, and Rs 3.04 crore (14.90%) in FY23. Any disruption in supply, termination of supplier relationships, or inability to source products from alternate suppliers on similar terms could negatively impact operations.
Get real-time IPO alerts on WhatsApp
Opening reminders • Subscription updates • GMP alerts • Allotment results
Start WhatsApp Alerts